For treatment, you still have Pfizer's Paxlovid and remdesivir. They might have a new monoclonal antibody as well, but I'm not certain. At this point, it's a nightmare to keep up with these because they make a new, completely unpronounceable one with every new variant, then when the virus inevitably mutates, they yank them off the market as fast as they added them.
Pfizer (makers of Paxlovid and the Comirnaty bivalent), Moderna (makers of Spikevax bivalent), Merck (makers of molnupravir), etc are never EVER going to allow ivermectin or hydroxychloroquine to get favorable attention from FDA or CDC. Regulatory capture costs a fortune and they are darn well going to get a ROI for their lobbying dollars.
The bivalent vaccines are still in play :(
Today the FDA issued a new schedule for when to get another booster.
Vaccines are for prevention.
For treatment, you still have Pfizer's Paxlovid and remdesivir. They might have a new monoclonal antibody as well, but I'm not certain. At this point, it's a nightmare to keep up with these because they make a new, completely unpronounceable one with every new variant, then when the virus inevitably mutates, they yank them off the market as fast as they added them.
Pfizer (makers of Paxlovid and the Comirnaty bivalent), Moderna (makers of Spikevax bivalent), Merck (makers of molnupravir), etc are never EVER going to allow ivermectin or hydroxychloroquine to get favorable attention from FDA or CDC. Regulatory capture costs a fortune and they are darn well going to get a ROI for their lobbying dollars.